Collection
MeSH Terms
thymoma, thymus cancer, thymus neoplasms, antineoplastic agent, drug therapy, chemotherapy, adjuvant chemotherapy, cancer adjuvant chemotherapy, cancer chemotherapy, cancer combination chemotherapy, combination chemotherapy, multimodality cancer therapy, antineoplastic combined chemotherapy protocols, surgery, thoracic surgery, thymectomy, sternotomy, radiotherapy, cancer radiotherapy, preoperative radiotherapy, systemic therapy, imatinib mesylate, imatinib, cixutumumab, sunitinib, saracatinib, everolimus, octreotide, pembrolizumab, nivolumab, atezolizumab, cisplatin, carboplatin, platinum, Gleevec, Glivec, Sutent, Zortress, Certican, Afinitor, Votubia, Evertor, Sandostatin, Bynfezia Pen, Keytruda, lambrolizumab, Opdivo, MDX1106, Tecentriq, MPDL3280A, CDDP, CBDCA, STI-571, ONO-4538, MK-3475, BMS-936558, thymic, thymus
Keywords
thymoma, thymus cancer, adjuvant chemotherapy, combination chemotherapy, cancer radiotherapy, systemic therapy
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Record Publish Year
2022
Publication Date
2022-03-10
Date of Last Evidence Search
2021-08-26
Methods Applied
Systematic review-based,
Evidence quality assessment,
Externally reviewed,
GRADE approach
Evidence quality assessment,
Externally reviewed,
GRADE approach
Guideline Contact
Emily Vella; [email protected]
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2022